Our journey on ALTA3263 clinical trial (tumors with KRAS mutations)

Great news!

@howleegirl That is awesome news. You have to be so excited to know that it is working?

YES, we are!! Been battling this cancer for 3.5 years now.

This is good news.
My friend has been battling his cancer for almost 2 years now. How can he enroll in this study?

He needs to ask his oncologist. Not sure everywhere this trial is. I'm sure it's not only in TN.
Good luck

@mayrox Here is a link for information on the trial. Please let me know, if you find it helpful? Thanks.
https://clinicaltrials.gov/study/NCT06835569

Hello, my mom has been on Alta3263 since January. Tumor has shrunk and been holding stable. Main side effect has been nausea that seems to be increasing over time. She’s also getting more and more lethargic even though CT’s show cancer is stable. Unclear if it is a side effect. She’s repeating CT every 6 weeks. Next one is this week. Thanks for sharing! Glad your husband is doing well!

@howleegirl

Hello, my mom has been on Alta3263 since January. Tumor has shrunk and been holding stable. Main side effect has been nausea that seems to be increasing over time. She’s also getting more and more lethargic even though CT’s show cancer is stable. Unclear if it is a side effect. She’s repeating CT every 6 weeks. Next one is this week. Thanks for sharing! Glad your husband is doing well!

My mom started the Alta 3263 trial in January 2016 after a lesion was found on her liver. The tumor has shrunk and been contained, but her nausea and lethargy has increased. Curious how others are handling it? Thanks

It is very encouraging that your mom's liver lesion has shrunk and remained controlled on ALTA-3263. That's wonderful to hear.

The increasing nausea and lethargy/fatigue are definitely worth discussing with the trial team. With an investigational drug, I would make sure they know exactly how much these symptoms have changed rather than assuming they are something she simply has to tolerate. The team may be able to adjust supportive medications, look for dehydration or electrolyte problems, or determine whether a dose modification or treatment break is appropriate under the trial protocol.

I would also ask them to check whether something besides the medication could be contributing—such as anemia, dehydration, nutrition, liver function, thyroid problems, infection, or other medications.

Has anyone else currently taking ALTA-3263 experienced increasing nausea or fatigue over time? If so, what has your trial team done that helped?